(0.08%) 5 184.82 points
(0.05%) 38 872 points
(-0.14%) 16 326 points
(0.11%) $78.57
(0.32%) $2.20
(-0.42%) $2 321.40
(-0.44%) $27.49
(2.38%) $987.85
(0.21%) $0.930
(0.88%) $10.92
(0.46%) $0.800
(-0.05%) $91.30
Quarter results today
(bmo 2024-05-07)
Expected move: +/- 14.35%
-12.92% $ 1.045
@ $0.930
Wydano: 14 vas. 2024 @ 16:30
Zwrot: 12.37%
Poprzedni sygnał: vas. 13 - 20:27
Poprzedni sygnał:
Zwrot: -2.14 %
Live Chart Being Loaded With Signals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 3.54M |
Średni wolumen | 3.19M |
Kapitalizacja rynkowa | 175.50M |
EPS | $0 ( 2024-05-02 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.830 |
ATR14 | $0.00500 (0.48%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-11 | Taveras Arthur | Sell | 14 235 | Common Stock |
2024-03-11 | Ragan Paula | Sell | 49 678 | Common Stock |
2024-03-11 | Mostafa Adam S. | Sell | 52 500 | Common Stock |
2024-03-11 | Dibiase Mary | Sell | 15 409 | Common Stock |
2024-02-13 | Arbet-engels Christophe | Buy | 180 816 | Stock Appreciation Right |
INSIDER POWER |
---|
80.18 |
Last 96 transactions |
Buy: 15 169 198 | Sell: 1 336 024 |
Wolumen Korelacja
X4 Pharmaceuticals Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ALZN | 0.945 |
FATE | 0.943 |
TCRT | 0.942 |
QTEK | 0.937 |
IMCC | 0.932 |
BVXV | 0.928 |
FNCH | 0.923 |
TTCF | 0.921 |
GRAY | 0.919 |
ARQQ | 0.919 |
10 Najbardziej negatywne korelacje | |
---|---|
DVCR | -0.955 |
BNIXU | -0.951 |
OPNT | -0.944 |
NTUS | -0.94 |
LMNX | -0.939 |
EWEB | -0.937 |
ISIG | -0.932 |
AVEO | -0.93 |
EDUT | -0.924 |
ITMR | -0.921 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
X4 Pharmaceuticals Inc Korelacja - Waluta/Towar
X4 Pharmaceuticals Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-2.00M (0.00 %) |
EPS: | $-0.570 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-2.00M (0.00 %) |
EPS: | $-0.570 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-1.99M (0.00 %) |
EPS: | $-1.480 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-3.99 |
Financial Reports:
No articles found.
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej